C. J. Edwards

The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients

C-S Yee, Vernon T. Farewell, David Isenberg et al. · Lara D. Veeken · 2011 · 207 citations · Full text

Hospitalization of individuals with systemic lupus erythematosus: characteristics and predictors of outcome

C. J. Edwards, T Y Lian, Humeira Badsha et al. · Lupus · 2003 · 121 citations

OP0169 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (104-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase 3, Randomized, Controlled Trials

Dafna D. Gladman, Arthur Kavanaugh, Ade Adebajo et al. · Annals of the Rheumatic Diseases · 2015 · 16 citations

OP0104 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis Including Current Skin Involvement: Results of a Phase 3, Randomized, Controlled Trial

C. Birbara, Francisco J. Blanco, Jeffrey Crowley et al. · Annals of the Rheumatic Diseases · 2013 · 15 citations

SAT0562 Long-Term (104-Week) Efficacy and Safety of Apremilast Monotherapy in Dmard-Naïve Patients with Psoriatic Arthritis: A Phase 3, Randomized, Controlled Trial and Open-Label Extension (Palace 4)

A. Wells, C. J. Edwards, Ade Adebajo et al. · Annals of the Rheumatic Diseases · 2015 · 14 citations